Patent Yard Sign in
Canadian application, no grantCanada

Medicaments

CA 2004301 A1 · Owner: Birch, Phillip J. · Inventors: Hayes, Ann G.; Birch, Phillip J.

CIPO record

Overview

Drawings and full text

Its claims, description and drawings are in the Canadian Patents Database.

Open the CIPO record

Abstract From the Canadian patent

The use of a compound of formula (I) or a physiologically acceptable salt or hydrate thereof in the treatment relief or, prevention of the effects of cerebral ischaemia (I), Compounds of formula (I) are described in UK Published Patent Application No. 2157691A, The compounds of formula (I) have been found to protect mammals including man, against neuronal damage resulting from cerebral ischaemia. The preferred compound for use in this indication is (?)-trans-5fluoro-2,3,3a,9a-tetrahydro-1H-1,4-benzodioxino2,3-c- pyrrole (formula (I), R = H, R1 = F, R2 - H), especially in the form of its hydrochloride salt.

Read the whole patent

Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.

Why it's free to use

  • Filed November 30, 1989. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 30, 2009.
  • A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 30, 2011.
  • We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledNovember 30, 1989
GrantedNo grant recorded
Term endedNovember 30, 2009
Patent numberCA 2004301 A1
Classification (IPC)A61K31/00 +1 more

Timeline

Timeline From CIPO dates

1990199219941996199820002002200420062008Application filedNov 30, 1989Term endedNov 30, 2009

Sources & verification

Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.